Fierce Healthcare

根据GSK刚刚发布不久的第三季度财报，GSK已终止24价肺炎球菌候选疫苗AFX3772针对成人的2期临床研究，将重点开发仍在临床前阶段的30价以上的肺炎疫苗，GSK预计在2025年将其推进临床。 AFX3772是GSK在2022年斥资33亿美元（21亿美元的预付款和12亿美元的潜在开发里程碑付款 ）收购Affinivax公司获得的主要项目之一。 对于放弃的原因，GSK发言人对FIERCE解释是因为竞争加剧。今年9月，Vaxcyte公司公布了其31价肺炎疫苗VAX-31在针对50岁及以上成年人中的1/2期临床研究数据，与辉瑞Prevnar 20的“头对头”比较表现亮眼。 当初GSK考虑收购Affinivax的时候，其与辉瑞就肺炎疫苗的竞争已进行到了白热化阶段，最直接的压力来自辉瑞手中的肺炎疫苗Prevnar系列。彼时，GSK手中10价肺炎疫苗Synflorix销售额在下滑，而辉瑞的Prevnar系列疫苗却顶住了疫情和政府采购的压力，销售额逆势不衰。此外，默沙东的Vaxneuvance的获批也进一步加剧了竞争的激烈程度。 GSK之所以押注Affinivax公司的AFX3772，当时重要的原因之一是在Affinivax公布的一项2期临床研究中，不论是否接种过默沙东的Pneumovax 23，AFX3772对某些血清型的免疫反应比辉瑞公司上一代Prevnar 13更高。 虽然此后辉瑞Prevnar 20 上市削弱了AFX3772在血清型覆盖方面的优势。不过，Affinivax认为自家产品的优势不仅限于此，其多抗原呈递系统MAPS要比传统的结合疫苗技术能诱导更广泛的保护性免疫反应。Affinivax的首席科学官Hal Barron博士曾在一份声明中提到，该平台在诱导B细胞和T细胞反应方面的表现吸引了GSK。 尽管这次GSK战略终止了针对AFX3772针对成人的肺炎研究，但GSK的发言人仍表示，相信Affinivax的多抗原递送系统的潜力。AFX3772针对儿童的2期临床研究还在继续进行。 编辑 | 姚嘉 yao.jia@PharmaDJ.com  总第2234期 访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

Company also named a Finalist in the Fierce Healthcare Innovation Awards OXFORD, England, Oct. 23, 2024 /PRNewswire/ -- Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected a winner of the Digital Health Hub Foundation: Digital Health Awards. Caristo was named a "Rising Star" in the Provider Diagnostics Category of the prestigious awards, presented Oct. 21 at the global HLTH 2024 conference in Las Vegas. Caristo's CaRi-Heart® cardiac risk prediction technology was the first innovation highlighted in the conference's opening ceremony by Jonathan Weiner, Founder, Chairman & CEO of HLTH. Continue Reading Caristo's CaRi-Heart Technology showcased at HLTH USA, global event Caristo has also been selected a finalist for the Fierce Healthcare Innovation Awards, from Questex, publisher of Fierce Healthcare, Fierce Biotech and Fierce Pharma. Caristo's flagship solution, CaRi-Heart technology, is one of five finalist solutions within the Artificial Intelligence Solutions category of the awards. Winners of the award will be announced Dec. 2. "We are deeply honored to be named a winner of the Digital Health Awards and a finalist for the Fierce Healthcare Innovation Award," said Frank Cheng, CEO of Caristo. "These dual recognitions are testimony to the depth of world-class clinical research validating CaRi-Heart's ability to transform cardiac care, as well as the real-world evidence provided by our clients." Caristo's proprietary CaRi-Heart technology is the only solution in the world that can uncover coronary inflammation, a hidden but treatable driver of heart disease progression. CaRi-Heart technology is commercially available in the European Union, the United Kingdom, and Australia and is currently seeking US Food & Drug Administration clearance. About Caristo Diagnostics Caristo Diagnostics is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world's #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by Nature as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X. About Digital Health Hub Foundation: Our mission is to help the world's next best innovative healthcare companies scale and grow. Founded in 2017, on the campus of UCSF in San Francisco, our now 30,000 member community consists of thousands of early-to late-stage healthcare companies and highly qualified healthcare industry providers, payors, experts, mentors, investors, clinicians and researchers who participate in our annual awards ceremony where we bring together the industry to honor and validate the best of the best and celebrate the technological advances in healthcare and the impact it has. Photo - Logo - SOURCE Caristo Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Intelligent prior authorization platform plus leading clinical criteria enhances provider experience, improves health plan efficiencies, and accelerates patients' time to high-quality care BOSTON and SEATTLE, Oct. 8, 2024 /PRNewswire/ -- Cohere Health®, a recognized leader in clinical intelligence and prior authorization automation, and MCG Health, part of the Hearst Health network and a leader in technology-enabled, evidence-based guidance, announced they will integrate their content and technology offerings to improve the prior authorization process for providers, patients, and health plans. The partnership's first joint health plan client is a large regional insurer that plans to launch the combined solution in early 2025. Continue Reading MCG Health - Part of The Hearst Health Network The partnership will seamlessly integrate MCG care guidelines into Cohere's Unify Decisioning automation tool to create an industry-leading solution for prior authorization decision-making, driving higher rates of clinically appropriate auto-approvals, while reducing provider submission time and friction. The collaboration between the two companies will significantly benefit joint health plan clients, their provider networks, and patients. For health plans, clinical review staff will be able to view indications pre-fulfilled by Cohere Models within MCG Cite CareWebQI, enabling much faster reviews. Patients stand to benefit the most from this partnership, as Cohere's AI-driven technology will reduce time to care, while MCG's widely accepted clinical guidelines will drive consistent, clinically appropriate care decisions. "The partnership between Cohere and MCG Health will provide a powerful, unified solution to reduce administrative burdens in prior authorization," said Jon Shreve, CEO, MCG Health. "Both organizations are respected as innovators in healthcare technology and together, we can accelerate our progress to support payers, providers, and most importantly, patients." "MCG Health is the perfect partner to complement Cohere's groundbreaking, AI-driven offering with industry-leading and nationally recognized clinical criteria," said Siva Namasivayam, CEO, Cohere Health. "Our leading, proven technology innovations applied to MCG's substantial clinical guidelines footprint will accelerate a new era of less prior authorization friction. Healthcare constituents are increasingly demanding innovative solutions that provide lower costs and faster access to care." For more information about the combined Cohere-MCG solution, please visit: . About Cohere Health Cohere Health is a clinical intelligence company that provides intelligent prior authorization as a springboard to better quality outcomes by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey. Currently processing nine million intelligent prior authorization requests annually, Cohere positively impacts more than 15 million health plan members and 492,000 healthcare providers nationwide. The company is a Top 5 LinkedIn™ Startup, winner of the TripleTree iAward, three-time recipient of KLAS Research's Points of Light, and has been named to Fierce Healthcare's Fierce 15 and CB Insights' Digital Health 150 lists. Cohere's investors include Deerfield Management, Define Ventures, Flare Capital Partners, Longitude Capital, and Polaris Partners. About MCG Health MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG's artificial intelligence and technology, infused with clinical expertise, enable its clients to prioritize and simplify their work. MCG's world-class customer service ensures its clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit . CONTACT: Kat Long anthonyBarnum Public Relations [email protected] Arri Stewart MCG Health Tel: (206) 389-5405 [email protected] SOURCE Cohere Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED